policy+practice

Eleven U.S. state-treasurers are asking drugmaker Gilead Sciences to lower the price of its experimental remdesivir treatment for Covid-19, arguing the company is attempting to market an “old drug at prices that are disconnected from economic reality.”

The National MS Society supports appropriate step therapy protections to ensure that people with MS can get access to the medications they need, without detrimental delays.

As drug prices escalate, politicians in Washington and states have sought to address the problem in limited ways, focusing mostly on insulin, which more than 7 million Americans rely on to manage diabetes and whose price more than doubled from 2012-17.

U.S. President Donald Trump on Monday suggested Pfizer Inc could secure the first U.S. approval of a COVID-19 vaccine in coming weeks.

New York spent an estimated $605 million on unnecessary drug costs delivered through Medicaid managed care organizations over a three-year period, because state officials didn’t ensure the use of the cheapest drugs.

Lowering prescription drug prices continues to be a top health care priority for Americans.

Why would pharma companies be OK with a Rose Garden event celebrating a $150 billion deal but then balk at a Rose Garden event that included the $100 cards?

Infections are a serious concern for people with CF, a fatal genetic disease that affects the lungs and digestive system.

As the backbone of the nation’s primary-care safety net, the 340B program is the only thing standing between our patients and unaffordable insulin and other lifesaving prescription drugs.

Allergan PLC defeated a proposed class action by employees who said they lost retirement savings because of the company’s participation in a generic drug price-fixing scheme.

The White House and the pharmaceutical industry were nearing a major deal to lower drug prices. Then the administration demanded that $100 cash cards be sent to millions of seniors before the election — and the industry balked.

Executive Order 13947 of July 24, 2020

Immunomedics is a cautionary tale about drug price controls.

Despite the announcements, the EOs are likely to face significant implementation challenges, as they would have to go through a lengthy rule-making process and many details are missing, making a complete assessment impossible.

NICE has announced its recommendation of Bristol-Myers Squibb’s blockbuster immunotherapy drug Opdivo (nivolumab) for the treatment of two non-small cell lung cancer (NSCLC) indications in the second-line.